Sandeep Sehgal, MD
Interventional Cardiology · Valparaiso, INNPI 1326066218
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,491 of the $22,435 with a category attached, or 60.1%. It is spread thinly across 27 manufacturers, the largest accounting for just 16.3%. Reporting peaked in 2022 at $5,459 and has fallen 58.4% since, to $2,269 in 2025.
Across 261 payments — averaging $85.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$4K
- Edwards Lifesciences$4K
- Boston Scientific$3K
- Bard Peripheral Vascular, Inc.$3K
- Penumbra, Inc.$3K
- Abiomed$2K
- plus $5K from 21 others
Across 4 payments — averaging $184.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$738
What the payments were for
- Consulting fees$4,90022%
- Grants$950%
- Travel & lodging$3,94918%
- Food & beverage$13,49160%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 9 | $3,647 |
| Edwards Lifesciences | 48 | $3,633 |
| Boston Scientific | 47 | $3,030 |
| Bard Peripheral Vascular, Inc. | 12 | $2,956 |
| Penumbra, Inc. | 9 | $2,629 |
| Abiomed | 32 | $1,940 |
| Medtronic(2 entities) | 28 | $1,579 |
| Shockwave Medical, Inc | 9 | $769 |
| W. L. Gore & Associates, Inc. | 6 | $318 |
| Abbott | 8 | $316 |
| Novartis | 12 | $310 |
| Johnson & Johnson | 7 | $280 |
| Terumo Medical Corporation | 2 | $174 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $134 |
| Lilly USA, LLC | 1 | $125 |
| Boehringer Ingelheim | 1 | $110 |
| Astellas Pharma US Inc | 4 | $105 |
| Biosense Webster, Inc. | 1 | $77 |
| BD | 1 | $71 |
| Pfizer | 3 | $51 |
| Cardiovascular Systems Inc. | 2 | $36 |
| Angiodynamics, Inc. | 2 | $35 |
| Stryker | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Gilead | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$5,692
- Indigo$3,359
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,467
- FLOWTRIEVER CATHETER, S$1,436
- WATCHMAN Access System$1,042
- Impella$1,027
- SAPIEN 3 Ultra RESILIA$703
- COREVALVE EVOLUT R$692
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$357
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$300
- WATCHMAN FLX$245
- JARDIANCE$235
- CoreValve Evolut$231
- Watchman$215
- COROFLOW$161
- METACROSS OTW$137
- Penumbra System$137
- LEQVIO$125
- XARELTO$114
- CARDIOFORM Septal Occluder$113
How this compares
$22,435 in reported general payments places this provider in the 85th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 956 | $1,048,099 |
| EntrestoSacubitril/Valsartan | 440 | $550,558 |
| XareltoRivaroxaban | 228 | $261,510 |
| MultaqDronedarone Hcl | 124 | $185,736 |
| Repatha SureclickEvolocumab | 105 | $107,615 |
| BrilintaTicagrelor | 110 | $84,080 |
| Praluent PenAlirocumab | 34 | $38,639 |
| Prasugrel Hcl | 213 | $34,793 |
| ClopidogrelClopidogrel Bisulfate | 2,158 | $19,950 |
| FarxigaDapagliflozin Propanediol | 11 | $17,384 |
| Metoprolol Succinate | 1,139 | $15,276 |
| Ranolazine ErRanolazine | 127 | $13,693 |
| Atorvastatin Calcium | 1,560 | $12,463 |
| Amiodarone Hcl | 224 | $8,559 |
| Niacin ErNiacin | 29 | $8,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $51 | $1,048,099956 claims |
| NovartisEntresto | $310 | $550,558440 claims |
| Johnson & JohnsonXarelto | $280 | $261,510228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Valparaiso
- Keith AtassiValparaiso$33K
- Anshuman DasValparaiso$19K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.